CoChat
Sign Up
Cited by 230Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

A Pilot Controlled Clinical Trial of ABT-418, a Cholinergic Agonist, in the Treatment of Adults With Attention Deficit Hyperactivity Disorder

Wilens, Timothy E., Biederman, Joseph, Spencer, Thomas J., Bostic, Jeff, Prince, Jefferson, Monuteaux, Michael C., Soriano, Jennifer, Fine, Catherine, Abrams, Annah, Rater, Michael, Polisner, David·1999·American Journal of Psychiatry
DOI 10.1176/ajp.156.12.1931
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, there is a paucity of controlled pharmacological trials. Recent reports have suggested the potential usefulness of cholinergic agents for ADHD. To this end, the authors completed a controlled study of ABT-418, a novel cholinergic activating agent, for the treatment of adults with ADHD. METHOD: This was a double-blind, placebo-controlled, randomized, crossover trial that compared a transdermal patch of ABT-418 (75 mg/day) to placebo in adults who met DSM-IV criteria for ADHD. There were two 3-week treatment periods separated by 1 week of washout. RESULTS: Of the 32 subjects enrolled in the study (88% were men; mean age = 40 years, SD = 9), 29 completed the study. At the endpoint of each active arm (last observation carried forward), a significantly higher proportion of subjects was considered improved while receiving ABT-418 than while receiving placebo (40% versus 13%). Similarly, at endpoint there was a significantly greater reduction in ADHD symptom checklist scores (28% versus 15%). Symptoms reflective of attention, and subjects with less severe ADHD, responded more robustly to ABT-418. Treatment with ABT-418 was relatively well tolerated; dizziness and nausea were the most frequently reported adverse effects. CONCLUSIONS: The results of this investigation indicate that ABT-418, a nicotinic analog, may be a potentially useful agent for the treatment of ADHD.

Overview

Integrity signals

Registry

Crossref · 10.1176/ajp.156.12.1931

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, Wasicak J, Williams M: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities, I: in vitro characterization. J Pharmacol Exp Ther 1994; 270:310–318
  2. NIMH: Clinical Global Impressions (CGI) scale. Psychopharmacol Bull 1985; 21:839–843
  3. Stein MA, Sandoval R, Szumowski E, Roizen N, Reinecke MA, Blondis TA, Klein Z: Psychometric characteristics of the Wender Utah Rating Scale: reliability and factor structure for men and women. Psychopharmacol Bull 1995; 31:423–431

Cited by

Sorted by citations

See all 230

Related

See all

Metadata

Authors
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., & Polisner, D.
Affiliations
Harvard University (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
1999-12-01
Volume
156
Issue
12
Pages
1931-1937
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/ajp.156.12.1931
OpenAlex
W2149138665
Cited by
230
References
50
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2021: 2 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 10
FWCI
8.80
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k20mh001175-02)
  • National Institute of Mental Health (MH-01175)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
ABT-418, attention deficit hyperactivity disorder, adult ADHD, cholinergic agonists, nicotinic agonists, transdermal patch, pharmacotherapy, ADHD symptom improvement, treatment tolerability
MeSH terms
Administration, Cutaneous, Adult, Age Factors, Attention Deficit Disorder with Hyperactivity, Dizziness, Double-Blind Method, Female, Humans, Isoxazoles, Male, Nausea, Pilot Projects, Pyrrolidines, Anti-Anxiety Agents, Treatment Outcome, Cross-Over Studies, Cholinergic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review